StocksMedium•3 November 2026•
1 min read
Analysts Raise Vertex Pharmaceuticals Price Targets Following FY2026 Guidance Hike
Key Facts
1Analysts raised price targets for Vertex Pharmaceuticals after Q3 sales beat estimates and the company hiked its FY2026 guidance.
2Shares rose 2.7% despite EPS of $4.76 missing the analyst estimate of $4.92.
Analysts raised price targets for Vertex Pharmaceuticals after Q3 sales beat estimates and the company hiked its full-year 2026 guidance. Benzinga reported that shares rose 2.7% despite the company posting earnings per share of $4.76, which fell short of the $4.92 analyst estimate.
VRTX closed at $553.15 on November 2, 2026, with the session seeing a trading range between a low of $544.09 and a high of $568.67. The market is currently prioritizing strong revenue growth and the improved fiscal year 2026 outlook over the slight miss in quarterly earnings per share.